The John W. Walsh Translational Research Award in Alpha-1 Antitrypsin Deficiency

Funding Agency:
Alpha-1 Foundation

This award is named after John W. Walsh, who dedicated his life’s work to finding a cure for Alpha-1 Antitrypsin Deficiency. Walsh and two others, all with Alpha-1 themselves, founded both the Alpha-1 Foundation and AlphaNet in 1995. Walsh’s leadership and passion have helped to shape the Alpha-1 Foundation into a successful organization and he is responsible for many of the Foundation’s accomplishments over more than two decades. Walsh has served on many voluntary health agencies and governmental advisory committees, often as chair. He has been awarded the Food and Drug Administration Commissioner’s Special Citation, the agency’s highest recognition, for his “pioneering collaboration in orphan drug development,” and many other honors. Walsh has always referred to himself as an “impatient patient,” and this award, aimed specifically at translating research findings into medical practice, is intended to carry on his commitment to a cure.

Deadline: Aug. 18, 2017

Agency Website

Eligibility Requirements

Eligible candidates for this award must have a clinical or research doctorate (including Ph.D., M.D., D.O., D.C., N.D., D.D.S., D.M.D., D.V.M., Sc.D., D.N.S., Pharm.D. or an equivalent doctoral degree). 

See the Alpha-1 website for complete program guidelines and proposal instructions.



Amount Description

Amount of Grant: up to $225,000 ($75,000/year) over three (3) years to fund one (1) award

Funding Type



Junior Faculty
Medical Fellow/Resident


Medical - Translational

External Deadline

August 18, 2017